TWINSS extension

Brief description of study

This is a 1-year extension to the core TWINSS study, open only to eligible participants from the core study who, in the opinion of the Investigator, may potentially derive clinical benefit from continued administration of CFZ533 (iscalimab). The purpose is to provide additional safety and tolerability information and further explore the pharmacokinetics (PK) and efficacy of the two doses of iscalimab. Participants will receive iscalimab q2wks and will continue to complete PROs and lab testing.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 09 Mar 2024. Study ID: 850965

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).